# US 2012/0237595 A1 · Methods for treating amyloidosis using 4-(amino)-2-(2,6-dioxo(3-piperidyl))- isoindoline-1,3-dione

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0237595 A1
- Document ID: US20120237595A1
- Status: Published application
- Kind: A1
- Application number: 13/483,832
- Filed: 2012-05-30
- Published: 2012-09-20
- Earliest claimed: 2002-05-17
- Assignees: Celgene Corporation
- Inventors: Jerome B. Zeldis
- Web page: https://patentgrep.com/patent/US20120237595A1

## CPC

- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/425: Thiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/515: Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A method of treating amyloidosis, which comprises administering to a patient having amyloidosis: (a) from about 1 mg to about 5 mg per day of a compound having the formula:
or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, and (b) 40 mg of dexamethasone.

### Claim 23

A method of treating amyloidosis, which comprises administering to a patient having amyloidosis: (a) from about 1 mg to about 5 mg per day of a compound having the formula:
or a pharmaceutically acceptable salt, solvate or stereoisomer thereof for 21 consecutive days followed by seven consecutive days of rest from administration of said compound in a 28 day cycle, and (b) 40 mg of dexamethasone per week.

### Claim 24 (depends on 22, 23)

The method of claim 22 or 23, wherein the amyloidosis is relapsed and refractory amyloidosis.

### Claim 25 (depends on 22, 23)

The method of claim 22 or 23, wherein the amyloidosis is refractory amyloidosis.

### Claim 26 (depends on 22, 23)

The method of claim 22 or 23, wherein the amyloidosis is relapsed amyloidosis.

### Claim 27 (depends on 22, 23)

The method of claim 22 or 23, wherein the patient has received previous therapy.

### Claim 28 (depends on 22, 23)

The method of claim 22 or 23, wherein the patient has demonstrated disease progression on previous therapy.

### Claim 29 (depends on 22, 23)

The method of claim 22 or 23, wherein the patient has received previous therapy and has demonstrated disease progression on previous therapy.

### Claim 30 (depends on 27)

The method of claim 27, wherein the previous therapy is treatment with thalidomide, 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, a proteasome inhibitor, melphalan, cyclophosphamide, or a combination thereof.

### Claim 31 (depends on 22, 23)

The method of claim 22 or 23, wherein the compound is administered in an amount of about 4 mg per day.

### Claim 32 (depends on 22, 23)

The method of claim 22 or 23, wherein the compound is administered in an amount of about 3 mg per day.

### Claim 33 (depends on 22, 23)

The method of claim 22 or 23, wherein the compound is administered in an amount of about 2 mg per day.

### Claim 34 (depends on 22, 23)

The method of claim 22 or 23, wherein the compound is administered in an amount of about 1 mg per day.

### Claim 35 (depends on 22)

The method of claim 22 or where the dexamethasone is orally administered in an amount of 40 mg once daily on days 1, 8, 15 and 22 of each 28 day cycle.

### Claim 36 (depends on 22, 23)

The method of claim 22 or 23, wherein the dexamethasone is orally administered in an amount of about 40 mg once a week of each 28 day cycle.

### Claim 37 (depends on 22, 23)

The method of claim 22 or 23, wherein the compound is administered in a capsule.

### Claim 38 (depends on 22, 23)

The method of claim 22 or 23, wherein the compound is administered in a tablet.

### Claim 39 (depends on 22, 23)

The method of claim 22 or 23, wherein the compound is administered orally in a capsule of 1 mg, 2 mg, 3 mg, or 4 mg.

### Claim 40 (depends on 39)

The method of claim 39, wherein the capsule comprises the compound, mannitol and pre-gelatinized starch.

### Claim 41

A method of treating amyloidosis, which comprises administering to a patient having amyloidosis: (a) from about 1 mg to about 5 mg per day of a compound having the formula:
for 28 consecutive days in a 28 day cycle, and (b) 40 mg of dexamethasone on at least one of days 1-21 of said cycle.

### Claim 42 (depends on 41)

The method of claim 41, wherein the compound is administered in an amount of about 4 mg per day.

### Claim 43 (depends on 41)

The method of claim 41, wherein the compound is administered in an amount of about 3 mg per day.

### Claim 44 (depends on 41)

The method of claim 41, wherein the compound is administered in an amount of about 2 mg per day.

### Claim 45 (depends on 41)

The method of claim 41, wherein the compound is administered in an amount of about 1 mg per day.

### Claim 46 (depends on 41)

The method of claim 41, wherein the dexamethasone is administered once daily on days 1, 8, 15 and 22 in a 28 day cycle.

### Claim 47 (depends on 41)

The method of claim 41, wherein the compound is administered in a capsule of 1 mg, 2 mg, 3 mg, or 4 mg.

### Claim 48 (depends on 47)

The method of claim 47, wherein the capsule comprises the compound, mannitol and pre-gelatinized starch.

### Claim 49 (depends on 22, 23)

The method of claim 22 or 23, wherein the compound is a pharmaceutically acceptable salt, solvate or stereoisomer.

### Claim 50 (depends on 22, 23, 41)

The method of claim 22, 23 or 41, which further comprises administering a therapeutically effective amount of aspirin.
